Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression

Journal of Acquired Immune Deficiency Syndromes

Volumn 50, Issue 5, 2009, Pages 457-463

  Peters, Lars ^a   Mocroft, Amanda ^b   Soriano, Vincent ^c   Rockstroh, Jürgen K ^d   Losso, Marcelo ^e   Valerio, Laure ^f   Aldins, Pauls ^g   Reiss, Peter ^h   Ledergerber, Bruno ⁱ   Lundgren, Jens D ^a,j  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d UNIVERSITY OF BONN   (Germany)

^e HOSPITAL RAMOS MEJÍA   (Argentina)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^g Infectology Centre of Latvia   (Latvia)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^j Rigshospitalet   (Denmark)

more..

Author keywords

Antiretroviral therapy; CD4; Hepatitis; HIV; Viral load

Indexed keywords

ABACAVIR; LAMIVUDINE PLUS ZIDOVUDINE; STAVUDINE; TENOFOVIR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD; CLASSIFICATION; CLINICAL TRIAL; DRUG COMBINATION; GENETICS; HEPATITIS C; MIDDLE AGED; MULTICENTER STUDY;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; VIRAL LOAD;

EID: 65449146754     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318198a0e1     Document Type: Article

References (20)

1. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003; 362:22-29.
2. Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis. 2005;192:992-1002.
3. Antonucci G, Girardi E, Cozzi-Lepri A, et al. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIVinfected individuals. Clin Infect Dis. 2005;40:101-109.
4. Braitstein P, Zala C, Yip B, et al. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program. J Infect Dis. 2006;193:259-268.
5. De LA, Bugarini R, Lepri AC, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med. 2002;162:2125-2132.
6. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000;356:1800-1805.
7. Klein MB, Lalonde RG, Suissa S. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2003;33:365-372.
8. Lincoln D, Petoumenos K, Dore GJ. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med. 2003;4:241-249.
9. Weis N, Lindhardt BO, Kronborg G, et al. Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study. Clin Infect Dis. 2006;42:1481-1487.
10. Sulkowski MS, Moore RD, Mehta SH, et al. Hepatitis C and progression of HIV disease. JAMA. 2002;288:199-206.
11. Sullivan PS, Hanson DL, Teshale EH, et al. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy. AIDS. 2006;20:1171-1179.
12. Yacisin K, Maida I, Ríos MJ, et al. Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy. AIDS Res Hum Retroviruses. 2008;24:935-940.
13. Mocroft A, Phillips AN, Ledergerber B, et al. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS. 2006;20:1141-1150.
14. Baillargeon JG, Paar DP, Wu H, et al. Psychiatric disorders, HIV infection and HIV/hepatitis co-infection in the correctional setting. AIDS Care. 2008;20:124-129.
15. Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med. 2003; 163:2187-2195.
16. Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol. 2006;44:47-55.
17. Verma S, Wang CH, Govindarajan S, et al. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C viruscoinfected patients? Clin Infect Dis. 2006;42:262-270.
18. Labarga P, Soriano V, Vispo ME, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIVinfected patients. J Infect Dis. 2007;196:670-676.
19. Soriano V, Maida I, Nunez M, et al. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferonbased therapies. Antivir Ther. 2004;9:987-992.
20. Rodriguez-Torres M, Rodriguez-Orengo JF, Rios-Bedoya CF, et al. Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: a paired liver biopsy study. J Hepatol. 2007;46:613-619.